Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study

被引：5

作者：

Palassin, Pascale ^{[1
]}

Maria, Alexandre T. J. ^{[2
,3
]}

Ladhari, Chayma ^{[1
]}

Quantin, Xavier ^{[4
]}

Montani, David ^{[5
,6
,7
]}

Bourdin, Arnaud ^{[8
,9
]}

Boissin, Clement ^{[8
]}

Fesler, Pierre ^{[9
,10
]}

Hillaire-Buys, Dominique ^{[1
]}

Guilpain, Philippe ^{[2
,3
]}

Faillie, Jean-Luc ^{[1
,11
]}

机构：

[1] Univ Hosp, Dept Med Pharmacol & Toxicol, Montpellier, France

[2] Montpellier Univ Hosp, St Eloi Hosp, Local Referral Ctr Rare Autoimmune Dis, Dept Internal Med Multiorgan Dis, Montpellier, France

[3] Univ Montpellier, IRMB, Montpellier, France

[4] Univ Montpellier, Montpellier Canc Inst, Dept Med Oncol, Thorac Oncol, Montpellier, France

[5] Univ Paris Saclay, Sch Med, Le Kremlin Bicetre, France

[6] Hop Marie Lannelongue, INSERM UMR S 999, Le Plessis Robinson, France

[7] Hop Bicetre, AP HP, Dept Resp & Intens Care Med, Le Kremlin Bicetre, France

[8] Univ Montpellier, CHU Montpellier, Dept Resp Dis, Montpellier, France

[9] Univ Montpellier, CNRS UMR 9214, INSERM U1046, PhyMedExp, Montpellier, France

[10] Montpellier Univ Hosp, Lapeyronie Hosp, Dept Internal Med & Arterial Hypertens, Montpellier, France

[11] Univ Montpellier, INSERM, IDESP, Montpellier, France

来源：

CANCER IMMUNOLOGY IMMUNOTHERAPY | 2022年 / 71卷 / 12期

关键词：

Pulmonary hypertension; Immune checkpoint inhibitors; Pharmacovigilance; Auto-immune disorders; Adverse drug reactions; ADVANCED CANCER; PNEUMONITIS;

D O I：

10.1007/s00262-022-03208-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibitors (ICI) restore immune response against cancer cells that can lead to immune-related adverse effects. While cardiovascular immune-related adverse effects are known to be associated with checkpoint inhibitors, recent case reports have raised concerns about the potential association with pulmonary hypertension (PH). By using the global pharmacovigilance database VigiBase, we investigated the onset of PH associated with ICI and propose a comprehensive description of the 42 cases of PH reported with ICI recorded in this database. Through this study and review of the cases published in the literature, we discuss the possible link between PH and ICI in the context of cancer in order to better understand this rare but potentially fatal event.

引用

页码：3093 / 3097

页数：5

共 13 条

[1] Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity
Escudier, Marion
Cautela, Jennifer
Malissen, Nausicaa
Ancedy, Yann
Orabona, Morgane
Pinto, Johan
Monestier, Sandrine
Grob, Jean-Jacques
Scemama, Ugo
Jacquier, Alexis
Lalevee, Nathalie
Barraud, Jeremie
Peyrol, Michael
Laine, Marc
Bonello, Laurent
Paganelli, Franck
Cohen, Ariel
Barlesi, Fabrice
Ederhy, Stephane
Thuny, Franck
[J]. CIRCULATION, 2017, 136 (21) : 2085 - 2087
[2] Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer
Fournel, Ludovic
Boudou-Rouquette, Pascaline
Prieto, Mathilde
Hervochon, Remi
Guinet, Claude
Arrondeau, Jennifer
Alexandre, Jerome
Damotte, Diane
Wislez, Marie
Batteux, Frederic
Icard, Philippe
Goldwasser, Francois
Alifano, Marco
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (04) : 497 - 505
[3] Releasing the brakes: a case report of pulmonary arterial hypertension induced by immune checkpoint inhibitor therapy
Glick, Matthew
Baxter, Chase
Lopez, David
Mufti, Kashif
Sawada, Stephen
Lahm, Tim
[J]. PULMONARY CIRCULATION, 2020, 10 (04)
[4] The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis
Ma, Ke
Lu, Yali
Jiang, Shanshan
Tang, Jiangong
Li, Xin
Zhang, Yuyang
[J]. FRONTIERS IN PHARMACOLOGY, 2018, 9
[5] Adverse effects of immune checkpoint inhibitor therapies on right ventricular function and pulmonary arterial dilatation
Mylvaganam, Ruben
Avery, Ryan
Goldberg, Isaac
Makowski, Courtney
Kalhan, Ravi
Villaflor, Victoria
Cuttica, Michael J.
[J]. PULMONARY CIRCULATION, 2021, 11 (01)
[6] Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer A Systematic Review and Meta-analysis
Nishino, Mizuki
Giobbie-Hurder, Anita
Hatabu, Hiroto
Ramaiya, Nikhil H.
Hodi, Stephen
[J]. JAMA ONCOLOGY, 2016, 2 (12) : 1607 - 1616
[7] Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment
Palaskas, Nicolas
Lopez-Mattei, Juan
Durand, Jean Bernard
Iliescu, Cezar
Deswal, Anita
[J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (02):
[8] Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis
Ponsoye, Matthieu
Frantz, Camelia
Ruzehaji, Nadira
Nicco, Carole
Elhai, Muriel
Ruiz, Barbara
Cauvet, Anne
Pezet, Sonia
Brandely, Marie Laure
Batteux, Frederic
Allanore, Yannick
Avouac, Jerome
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (12) : 2142 - 2149
[9] Non-suppressive regulatory T cell subset expansion in pulmonary arterial hypertension
Sada, Yoshiharu
Dohi, Yoshihiro
Uga, Sayuri
Higashi, Akifumi
Kinoshita, Hiroki
Kihara, Yasuki
[J]. HEART AND VESSELS, 2016, 31 (08) : 1319 - 1326
[10] Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
Salem, Joe-Elie
Manouchehri, Ali
Moey, Melissa
Lebrun-Vignes, Benedicte
Bastarache, Lisa
Pariente, Antoine
Gobert, Aurelien
Spano, Jean-Philippe
Balko, Justin M.
Bonaca, Marc P.
Roden, Dan M.
Johnson, Douglas B.
Moslehi, Javid J.
[J]. LANCET ONCOLOGY, 2018, 19 (12) : 1579 - 1589

← 1 2 →